retatrutide eli lilly press release 2024 2025 Lilly's Phase 3 clinical studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments Retatrutide Exhibits Meaningful Weight Loss

#FoodSafety #FMCG #RegulatoryCompliance #CleanLabel #CPGIndustry #StateRegulation #Reformulation To view or add a comment, sign in CPG analysts are reading the GLP-1 story too uniformly

Since eating habits influence the quantity and type of food consumed, they can prevent or control obesity, making them modifiable factors

The bottom line In clinical trials, retatrutide has produced unprecedented levels of weight loss for a medication, and the data suggest that it is a very effective diabetes drug as well

Noom Med provides medical-guided weight loss in the palm of your hand

This translates to dropping 4-5 clothing sizes and significant improvements in energy levels, joint comfort, and overall mobility